Mirum Pharmaceuticals(NASDAQ) MIRM

Mirum Pharmaceuticals, Inc. helps people with rare liver diseases. It makes medicines that reduce itching and improve digestive health. These drugs treat children and adults with few medical options.

Medicines for Rare Conditions

• LIVMARLI: Oral medication that blocks specific proteins to reduce itching; generated $128.7 million in sales for the three months ended June 30, 2026.
• Bile Acid Medicines: CHOLBAM and CTEXLI capsules for treating enzyme defects; generated $47.5 million in sales for the three months ended June 30, 2026.
• Research Pipeline: Clinical candidates such as volixibat and brelovitug targeting inflammatory liver conditions and chronic hepatitis D.

Expanding the Pipeline

• Acquired Bluejay Therapeutics on Jan. 23, 2026, to obtain the drug candidate brelovitug for chronic hepatitis D.
• Obtained development rights for the bone disease drug zilurgisertib through an agreement with Incyte in April 2026.
• Partnered with Takeda for the Japanese market, where LIVMARLI received regulatory approval in March 2025.
• Completed enrollment for the EXPAND Phase 3 study in the first half of 2026 for LIVMARLI label expansion.

Building a Global Network

Mirum manages specialized commercial operations with dedicated teams in the U.S., Canada, and certain European markets. The company focuses on acquiring and in-licensing late-stage drug candidates to build a portfolio of therapies for rare orphan conditions.

By the Numbers

• Total product sales reached $176.2 million for the three months ended June 30, 2026.
• LIVMARLI sales were $128.7 million for the three-month period ended June 30, 2026.
• Net loss for the six months ended June 30, 2026, was $857.4 million.
• Unrestricted cash and investments totaled $561.3 million as of June 30, 2026.
• The company reported an accumulated deficit of $1.5 billion as of June 30, 2026.

Bottom Line

Mirum has transitioned from a development-stage firm to a commercial-stage company with three approved medicines. Its growth relies on expanding existing product uses and acquiring new candidates for rare diseases.